Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states.

Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS.

Neuropharmacology. 2015 Sep;96(Pt B):235-43. doi: 10.1016/j.neuropharm.2014.12.028. Epub 2015 Jan 9. Review.

PMID:
25582289
2.

Clinical Characteristics of Children and Adolescents with a Primary Tic Disorder.

Specht MW, Woods DW, Piacentini J, Scahill L, Wilhelm S, Peterson AL, Chang S, Kepley H, Deckersbach T, Flessner C, Buzzella BA, McGuire JF, Levi-Pearl S, Walkup JT.

J Dev Phys Disabil. 2011 Feb;23(1):15-31.

3.

Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

Quik M, Zhang D, Perez XA, Bordia T.

Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. Review.

4.

Similar activity of mecamylamine stereoisomers in vitro and in vivo.

Papke RL, Stokes C, Muldoon P, Imad Damaj M.

Eur J Pharmacol. 2013 Nov 15;720(1-3):264-75. doi: 10.1016/j.ejphar.2013.10.018. Epub 2013 Oct 23.

5.

Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics.

Zurkovsky L, Taylor WD, Newhouse PA.

Biochem Pharmacol. 2013 Oct 15;86(8):1133-44. doi: 10.1016/j.bcp.2013.07.032. Epub 2013 Aug 8. Review.

6.

Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders.

De Nadai AS, Storch EA, McGuire JF, Lewin AB, Murphy TK.

J Cent Nerv Syst Dis. 2011 Jun 1;3:125-42. doi: 10.4137/JCNSD.S6616. Print 2011.

7.

Current controversies on the role of behavior therapy in Tourette syndrome.

Scahill L, Woods DW, Himle MB, Peterson AL, Wilhelm S, Piacentini JC, McNaught K, Walkup JT, Mink JW.

Mov Disord. 2013 Aug;28(9):1179-83. doi: 10.1002/mds.25488. Epub 2013 May 16. Review.

8.

Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Sanberg PR, Vindrola-Padros C, Shytle RD.

Physiol Behav. 2012 Dec 5;107(5):801-8. doi: 10.1016/j.physbeh.2012.06.023. Epub 2012 Jul 6. Review.

9.

Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Arnold LE, Aman MG, Hollway J, Hurt E, Bates B, Li X, Farmer C, Anand R, Thompson S, Ramadan Y, Williams C.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):198-205. doi: 10.1089/cap.2011.0056. Epub 2012 Apr 26.

10.

Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale.

Storch EA, De Nadai AS, Lewin AB, McGuire JF, Jones AM, Mutch PJ, Shytle RD, Murphy TK.

J Child Adolesc Psychopharmacol. 2011 Dec;21(6):621-7. doi: 10.1089/cap.2010.0149. Epub 2011 Nov 9.

11.
12.

Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis.

Mineur YS, Picciotto MR.

Trends Pharmacol Sci. 2010 Dec;31(12):580-6. doi: 10.1016/j.tips.2010.09.004. Epub 2010 Oct 19. Review.

13.

Contemporary assessment and pharmacotherapy of Tourette syndrome.

Scahill L, Erenberg G, Berlin CM Jr, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J; Tourette Syndrome Association Medical Advisory Board: Practice Committee.

NeuroRx. 2006 Apr;3(2):192-206. Review.

14.

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.

Sacco KA, Bannon KL, George TP.

J Psychopharmacol. 2004 Dec;18(4):457-74. Review.

Items per page

Supplemental Content

Write to the Help Desk